Monopar Therapeutics (NASDAQ:MNPR)announces that its Phase 1b open-label dose-escalation trial of camsirubicin in the U.S. is active and recruiting patients.
The trial is evaluating the safety and anti-tumor activity of increasing doses of camsirubicin in combination with growth factor support (pegfilgrastim/G-CSF) for the treatment of advanced soft tissue sarcoma (ASTS).
The goal is to determine whether escalating doses of camsirubicin result in an increased anti-cancer effect in patients with ASTS, while also maintaining an appropriate safety profile.
"Camsirubicin has already shown anti-tumor activity comparable to doxorubicin in a pilot study in ASTS patients, without any signs of irreversible heart damage," Chief Scientific Officer Andrew Mazar said.